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Oestrogen exposure has been considered to be one of the main risk
factors for breast cancer. One characteristic of oestrogen is its
mitogenic action in hormone-sensitive tissues such as uterus and
breast. More recently, interest has also focused on the possible
carcinogenic influence from oestrogen metabolites. These metabo-
lites may mediate their effect by; activation of the classical
oestrogen receptor, interaction with other specific receptors or
effectors, direct binding to DNA, or by other mechanisms
(reviewed by Zhu and Conney, 1998). Among the oestrogen
metabolites, the two catechol oestrogens, 2-hydroxyoestradiol (2-
OHE2) and 4-hydroxyoestradiol (4-OHE2), have shown several
biological effects (Weisz, 1994; Liehr, 1997; Zhu and Conney,
1998). The 4-hydroxyolated metabolite binds to and activates the
oestrogen receptor with approximately the same affinity as oestra-
diol. However, the interaction with the hormone receptor is
markedly reduced for the 2-OHE2, which therefore may possess a
weaker hormonal potency as compared with the parent hormone;
oestradiol (Liehr, 1997; Zhu and Conney, 1998). Both animal
models and in vitro studies (reviewed by Liehr, 1997) have shown
that 4-OHE2 promotes cell proliferation and carcinogenesis.
Furthermore, Liehr and Ricci (1996) observed elevated 4-OHE2
levels in human breast cancer tissue as compared to normal breast
tissue and in addition, both 2- and 4-OHE2 have been reported to
undergo metabolic oxidation to the chemically highly reactive
oestrogen-derived semiquinones and quinones (Liehr and Yager,
1996; Cavalieri et al, 1997). These metabolites are possible candi-
dates as agents in the carcinogenic process. Their interaction with
DNA may cause formation of adducts and furthermore in the
semiquinones/quinones redox cycling processes, reactive oxygen
species such as superoxide are formed (Cavalieri et al, 1997; Zhu
and Conney, 1998). Free radicals have been demonstrated to
damage both DNA and other cellular constituents and such
damage seems likely to be an important event in the aetiology of
human cancers (Dreher and Junod, 1996; Marnett, 2000). One of the
major inactivation pathways of 2- and 4-OHE2 is through O-methy-
lation to 2- and 4-methoxyoestradiol (Yager and Liehr, 1996; Zhu
and Conney, 1998). These metabolites are more lipophilic, have
longer half-lives than their corresponding OHE2, and they have a
weak or no binding affinities to the classical oestrogen receptor
(Zhu and Conney, 1998). Interestingly, 2-methoxyoestradiol (2-
MeE2) has been reported to influence carcinogenesis by inhibition
of endothelial cell proliferation, and migration and angiogenesis
(Fotsis et al, 1994). 
The O-methylation of 2- and 4-OHE2 is catalysed by the
enzyme Catechol-O-Methyltransferase (COMT) (Yager and Liehr,
1996). COMT activity is highly present in liver and kidney, and it
is also found at significant levels in brain, red blood cells, uterine
endometrium and the mammary gland. The COMT gene, located
on chromosome 22q11.1–q11.2, contains a single-nucleotide
polymorphism (G→ A) in codon 158/108 of the membrane
bound/cytosolic form (Butterworth et al, 1996). The single-
nucleotide transition results in an amino acid change, Val→ Met,
which has been shown to determine high- and low-activity alleles
of the enzyme (Lachman et al, 1996). The COMTMet allele, coding
for the low-activity and heat-labile enzyme, has proved to be 4- to
5-fold less effective in methylating catechol substrates in vitro
(Scanlon et al, 1979). A possible accumulation of 4-OHE2, caused
by decreased COMT activity is hypothesized to confer increased
risk of breast cancer. 
The aetiology of breast cancer in young women has shown
differences in terms of inheritance, carcinogenesis and prognosis
compared to their older counterparts (Nixon et al, 1994; Bonnier
et al, 1995), possibly indicating separate biological origin of the
disease. Besides germ-line mutations in the breast cancer suscepti-
bility genes (i.e., BRCA1 and BRCA2), little is known about other
factors implicated in breast carcinogenesis among young women.
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menopause, age at first full-time pregnancy as well as the number
of parturitions, are indicators of cumulative oestrogen exposure.
The cellular levels of oestrogen and its metabolites may be
controlled through both genetic and environmental factors. We and
others have hypothesized that polymorphisms in crucial genes,
e.g. genes coding for enzymes involved in oestrogen metabolism,
may be predisposing for breast cancer. In a previous investigation,
of one SNP in the CYP17 gene, done on the same populations as
the present study, a significant association between genetic vari-
ants and breast cancer risk was found (Bergman-Jungeström et al,
1999). Also, other studies of genetic polymorphism in genes
involved in the biosynthesis or metabolism of endogenous and
exogenous carcinogens have shown association to altered breast
cancer risk and tumour progression (Zhong et al, 1993; Taioli et al,
1995; Lundin et al, 1999; Sprudle et al, 2000). 
The intention with the present study was to investigate the
conceivable association between the low-activity COMT gene and
risk of early onset breast cancer. We analysed frequencies of the
Val/Met alleles in a group of young breast cancer patients and
compared with a control population consisting of young healthy,
female blood donors. 
MATERIALS AND METHODS 
Study population 
The study included 126 young breast cancer patients diagnosed in
the South-East Sweden Health Care Region between 1980 and
1994. At the time of diagnosis, the patients were between 22 and
36 years of age, with a median age of 34 years. Tissue samples
from archival material were obtained from the pathology depart-
ments of hospitals in Linköping, Norrköping, Jönköping and
Kalmar. The control group included 117 healthy female blood
donors who were between 18 and 39 years of age (median age 30
years). Blood from the control population was collected in EDTA
tubes. 
Methods 
A microdissection technique was used to prevent contamination
with malignant cells. A 5-µ m section from each paraffin block of
axillary lymph nodes was stained with haematoxylin-eosin, and
areas comprises normal cells were selected by a pathologist. The
selected areas were then identified in the 30-µ m sections and
collected, before preparation of DNA. The paraffin was removed
by repeated extractions with xylene, followed by hydration in
decreasing concentrations of ethanol. The tissue was then digested
in a proteinase K solution at 55˚C for 36 hours, and by-products
were subsequently extracted with phenol, phenol-chloroform
(1:1), and chloroform. The nucleic acids were precipitated in 95%
ethanol containing sodium acetate (0.1 M) for approximately 1
hour at –20˚C and thereafter pelleted by centrifugation at 12 000 g.
The DNA pellet was washed in 70% ethanol, vacuum dried and
then resuspended in water. 
Samples from the control population were purified using a rapid
DNA preparation method (Wizard Genomic DNA Purification
System, Promega). Erythrocytes were lysed before the leucocytes
were isolated by centrifugation. The leucocytes were then suspended
in a nuclei lysis solution, and proteins were precipitated and
removed by centrifugation. Thereafter, the DNA was precipitated in
isopropanol. The pelleted DNA was washed with 70% ethanol,
dried and finally resuspended in 10 mM Tris-HCl/1 mM EDTA
(pH 4.0). The concentration of DNA, from both cases and
controls, was determined by spectrophotometry. 
Identification of and screening for A1/A2 alleles 
Polymerase chain reaction (PCR) amplification of a 237 base-pair
DNA fragment of the COMT gene, including the part of exon 4
containing the polymorphism, was performed using the forward
primer COMT E4U-2 (5´-TACTGTGGCTACTCAGCTGTGC-3´)
and the reverse primer COMT E4L-2 (5´-GTGAACGTGGTGT-
GAACACC-3´) (Lavigne et al, 1997). PCR reactions were carried
out in 21 µ l aliquots containing 25–50 ng of genomic DNA,
primers (each 1.0 µ M), 1 × reaction buffer, dNTPs (each 200 µ M)
and 1 unit of Taq polymerase (Promega). We performed 30–40
cycles of PCR amplification, with denaturation at 93˚C for 45 s,
annealing at 55˚C for 1 min, and extension at 72˚C for 1 min. An
initial 3 min denaturation step at 94˚C and a final 4 min extension
at 72˚C were used. The PCR products were incubated with the
restriction enzyme Nla III (New England Biolabs) for 3 h at 37˚C.
The enzyme was subsequently denatured at 60˚C for 20 min and
the amplicons were separated by agarose (3%) gel electrophoresis.
The gel was stained with ethidium bromide and the DNA was
visualized in UV light. Restriction products of 27, 42 and 54 base
pairs were present in every sample. The presence of a G at position
1947 (COMTVal allele) generates a unique 114 base-pair fragment,
while the occurrence of an A (COMTMet allele) resulted in diges-
tion of the 114 base-pair fragment into products of 96- and 18-base
pairs respectively (Figure 1). 
Statistical methods 
Odds ratios (OR) were calculated to estimate the risk of breast
cancer and P values were calculated by χ 2-analysis. Furthermore,
χ 2 test was also used to investigate whether the control population
was consistent with the Hardy–Weinberg equilibrium. 
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Figure 1 Nla III restriction fragments of COMT alleles separated by
agarose gel electrophoresis. The presence of a G at position 1947 (COMTVal
allele) generates a unique 114 base pair fragment, while the occurrence of an
A (COMTMet allele) results in digestion of the 114 base pair fragment into
products of 96- and 18-base pairs respectively. Line L contains a 100-base
pair ladder. Lane 4 and 6 show a homozygous low activity allele
(COMTMet/COMTMet, lane 8 the homozygous high-activity allele
(COMTVal/COMTVal) and lane 1, 2, 3, 5 and 7 the heterozygous pattern 
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Odds ratios were calculated to evaluate the risk of breast cancer for
individuals homozygous or heterozygous for the low-activity allele,
COMTMet/COMTMet, COMTVal/COMTMet and COMTMet/COMTMet +
COMTVal/COMTMet, compared to subjects who were homozygous for
the high-activity allele; COMTVal/COMTVal. The frequencies of the
COMT genotype among the breast cancer patients and the control
population are shown in Table 1 in addition to the calculated odds
ratios and P values. We found no increased breast cancer risk
among low-activity allele carriers compared to individuals who
were homozygous for the COMTVal allele. The COMTMet/COMTMet
carriers had an OR of 0.87, 95% confidence interval (CI), 0.34–2.2, 
P = 0.74. OR among the heterozygous women was 0.85; CI:
0.35–2.1,  P = 0.70, and when COMTMet/COMTMet +
COMTVal/COMTMet alleles were considered together the OR was esti-
mated to 0.86; (CI), 0.37–2.00, P = 0.70. Moreover, the genotype
dispersal in the control population was within that expected
according to the Hardy–Weinberg equilibrium. 
DISCUSSION 
It has been hypothesized that women, homo-or heterozygous for
the COMTMet allele, may exhibit lower COMT activity in the
breast. Decreased COMT activity may result in an accumulation of
potentially carcinogenic oestrogen metabolites, and therefore
cause a higher risk of breast cancer. This has been tested in both
post-and premenopausal women by several investigators (Lavigne
et al, 1997; Thompson et al, 1998; Millikan et al, 1998; Huang et al,
1999) but the results are discordant. In the present study,
comprising early-onset breast cancer patients and a control popula-
tion of young blood donors, Val/Met polymorphism revealed no
association with altered breast cancer risk. This finding is consis-
tent with that reported by Millikan et al (1998), who performed a
population-based case–control study including 654 invasive breast
cancer cases and 642 controls of both pre- and postmenopausal
women. No association between one or more copies of the low-
activity COMT allele and breast cancer risk was found. A similar
result was obtained by Thompson et al (1998), when risk was esti-
mated in a case–control study consisting of both pre- and post-
menopausal subjects in a study based on 281 breast cancer patients
and 289 controls. Nevertheless, when the study population was
stratified according to menopausal status, the COMTMet allele was
associated with breast cancer risk among premenopausal individ-
uals but, interestingly they found an inverse association in post-
menopausal women. In contrast to the results obtained by
Thompson et al, Lavigne and co-workers (1997) reported a trend
towards increased breast cancer risk in postmenopausal women
homozygous for the COMTMet allele and further, their results
slightly indicate a decreased risk for the premenopausal subjects.
A recent Taiwanese population case–control study, in which 150
patients and 150 controls were examined, revealed a significant
increase in breast cancer risk associated to the COMTMet/Met geno-
type (Huang et al, 1999). The homozygous pattern of the COMTMet
allele was associated with higher risk in the postmenopausal
women compared to their premenopausal counterparts. However,
it should be noted that the number of participants with
COMTMet/Met genotype were few. 
Earlier studies of the COMT gene polymorphism, investigating
its possible role as a modifier of breast carcinogenesis, indicate the
importance of considering other parameters closely related to
oestrogen exposure (Lavigne et al, 1997; Millikan et al, 1998;
Thompson et al, 1998; Huang et al, 1999). One such parameter is
body mass index (BMI), which has been shown to affect oestrogen
exposure, possibly as a result of aromatization of androgens to
oestrogens in fat tissue (Ackerman et al, 1981). Body mass index
has been noted to influence breast cancer risk in several studies,
and this effect may differ depending on menopausal status.
Postmenopausal adipose women have been reported to be at higher
risk of breast cancer compared to their leaner counterparts, while a
decreased risk has been observed in premenopausal women with
high BMI (Harris et al, 1992; Magnusson et al, 1998; van den
Brandt, 2000). Most of the cases in the present study were diag-
nosed in the 1980s and data about BMI were not collected; conse-
quently information about BMI is not available. Considering the
combination of BMI and COMT genotype, the results are mainly
compatible. Lavigne et al (1997) found that high BMI, in combi-
nation with the homozygous low-activity COMT genotype, signif-
icantly increased breast cancer risk (OR, 3.6) in postmenopausal
women. Thompson and co-workers (1998) demonstrated that high
BMI and presence of at least one COMTMet allele was associated
with a significant breast cancer risk in premenopausal women, but
no such correlation among the postmenopausal women was
shown. 
In summary, there are several reports indicating an influence
from oestrogen metabolites on cellular properties closely related to
carcinogenesis. A reduced COMT activity may result in enhanced
cell proliferation and increased formation of free radicals as a
consequence of a possible accumulation of 4-OHE2 and further-
more a decreased inhibition of angiogenesis due to less synthesis
of 2-MeE2. Yet, the present case–control study examining young
breast cancer patients and age-matched controls, did not show any
increased breast cancer risk associated with the low-activity
COMT genotype. Our result indicates that the investigated genetic
COMT gene polymorphism and breast cancer risk 861
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Table 1 Calculated odds ratios (ORs), COMT genotype- and allele frequencies for young breast cancer
patients and a control population 
Genotype Control (%)  Cases (%)  OR 95% CI P
(n = 117) (n = 126)
COMTVal/Val 13 (11) 16 (13) 1.0 
COMTVal/Met 61 (52) 64 (51) 0.85 0.35–2.1 0.70 
COMTMet/Met 43 (37) 46 (36) 0.87 0.34–2.2 0.74 
COMTVal/Met + COMTMet/Met 104 (89) 110 (87) 0.86 0.37–2.0 0.70 
Allele frequencies 
COMTVal 87 (37) 96 (41) 
COMTMet 147 (58) 156 (62) 
COMTVal = high activity allele; COMTMet = low activity allele. 
BJOC 01-2009 859-862  10/9/01  2:07 pm  Page 861variant of COMT may not alone be an important risk factor in
young women. Polymorphisms in crucial genes are probably asso-
ciated with a more modest breast cancer risk as compared to the
highly penetrant germ-line mutations in breast cancer suscepti-
bility genes (e.g., BRCA1 and  BRCA2). Nevertheless, genetic
polymorphisms are prevalent in the general population and may
therefore explain a greater proportion of breast cancer than muta-
tions in the highly penetrant genes (Weber and Nathanson, 2000).
Genetic variants in combination with multiple endogenous and
exogenous factors may significantly increase breast cancer risk. 
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